Sentia Medical Sciences Extends its Research Collaboration with Neurocrine Biosciences to Discover Novel Peptide Therapies for HPA-Driven Diseases
Shots:
- Sentia will receive committed research funding to support discovery efforts & is eligible to receive milestones along with royalty based on products that emerge from the collaboration
- The collaboration will use Sentia’s peptide-based platform & Neurocrine’s drug development expertise in CRF biology to develop and commercialize therapies for a variety of hypothalamic-pituitary-adrenal axis modulated diseases
- The companies collaborated to discover novel peptide antagonists targeting CRF and advances for the development candidate stage while Neurocrine will be responsible for all further development, manufacturing, regulatory, and commercial activities
Ref: Globenewswire | Image: Sentia Medical Sciences
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
